KRAS and pancreatic intraductal papillary-mucinous neoplasm: Some studies reveal that IPMN in the pancreatic ducts could originate from the synergism of KrasG12D and LKB1 mutations.[52] In one study, conditionally expressed Kras and Lkb1 mutations in adult pancreatic ducts were used to create a mouse model.